Slovenia, situated in Central Europe with a population of 2.1 million, has an estimated 44,278 individuals with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia, rendering them potential candidates for disease-modifying treatment (DMT), such as lecanemab. We identified 114 potential candidates whose real-life expenses for diagnostic process surmount to more than €80,000. Treating all potential candidates nationwide would amount to €1.06 billion, surpassing Slovenia’s entire annual medication expenditure for 2022 (€743 million). The introduction of DMTs and the associated logistics, along with potential complications, will significantly change societal, professional, and patient approach to treatment of Alzheimer’s disease.
WimoA, SeeherK, CataldiR, CyhlarovaE, DielemannJL, FrisellO, GuerchetM, JönssonL, MalahaAK, NicholsE, PedrozaP, PrinceM, KnappM, DuaT (2023) The worldwide costs of dementia in 2019. Alzheimers Dement19, 2865–2873.
3.
ŽupaničE, WimoA, WinbladB, KrambergerMG (2022) Cost of diagnosing and treating cognitive complaints: One-year cost-evaluation study in a patient cohort from a Slovenian memory clinic. Zdr Varst61, 76–84.
Van DyckCH, SwansonCJ, AisenP, BatemanRJ, ChenC, GeeM, KanekiyoM, LiD, ReydermanL, CohenS (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med388, 9–21.
8.
Lilly, Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease, https://investor.lilly.com/node/48836/pdf
Eisai, EISAI’S approach to U.S. pricing for Leqembitrademark (lecanemab), a treatment for early Alzheimer’s disease, sets forth our concept of “societal value of medicine” in relation to “price of medicine”, https://www.eisai.com/news/2023/news202302.html, Accessed 11.8.2023.
11.
ManlyJJ, JonesRN, LangaKM, RyanLH, LevineDA, McCammonR, HeeringaSG, WeirD (2022) Estimating the prevalence of dementia and mild cognitive impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project. JAMA Neurol79, 1242–1249.
12.
DengY, ZhaoS, ChengG, YangJ, LiB, XuK, XiaoP, LiW, RongS (2021) The prevalence of mild cognitive impairment among Chinese people: A meta-analysis. Neuroepidemiology55, 79–91.
13.
LuckT, Riedel-HellerSG, KaduszkiewiczH, BickelH, JessenF, PentzekM, WieseB, KoelschH, van den BusscheH, AbholzH-H, MoeschE, GorferS, AngermeyerMC, MaierW, WeyererS (2007) Mild cognitive impairment in general practice: Age-specific prevalence and correlate results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Dement Geriatr Cogn Disord24, 307–316.
14.
OvertonM, PihlsgårdM, ElmståhlS (2019) Prevalence and incidence of mild cognitive impairment across subtypes, age, and sex. Dement Geriatr Cogn Disord47, 219–232.
15.
GustavssonA, NortonN, FastT, FrölichL, GeorgesJ, HolzapfelD, KirabaliT, Krolak-SalmonP, RossiniPM, FerrettiMT (2023) Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement19, 658–670.
